Fig 6. FTC-133 cell viability upon PLEO co-administration (0.04% v/v, 320 μg/ml) with increasing doses of CDDP (5–80 μM), 5-FU (25–500 μM), and VP16 (5–100 μM) for 6, 24, and 48 h.

Data are expressed as mean ± SD (n = 3). *p<0.05 vs. untreated cells.